BNET Industries

Roche Holding AG

RHHBY is in the Pharma Industry

Market Cap:$112.6B
Last Fiscal Year Sales:$32.4B
  • Public
  • CH
Dow Jones Description

Roche's focus is health. Roche Holding Ltd. (OTC: RHHVF (ADR) Swiss) was founded in 1896 and is headquartered in Basel, Switzerland. The company operates in two segments, which are pharmaceuticals and diagnostics. Its drugs include Accutane, Herceptin, Invirase, Rituxan, Rocephin, Tamiflu, and Xenical, among others. It owns 60% of Genentech and 51% of Chugai Pharmaceutical. The company has annual revenue of about $27 billion and employs about 68,000 people. In 2005, it sold its consumer healthcare division to Bayer, allowing it to focus on core business.In July 2005 the company acquired GlycArt Biotechnology AG, a privately owned Swiss biotech company that provides technology for enhancing the efficacy of antibodies will further strengthen Roche's expertise in therapeutic antibody research and development.

Chief Executive Officer
Severin Schwan
Number of Employees 80,080
Contact Information

Grenzacherstrasse 124

Basel CH-4070

www.roche.com

(41) 616881111

NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413

Recent Events

  • Roche announces late-stage trial for heart drug

    11/18/09 - Joint Venture / Alliance - View Story

  • AstraZeneca lifted to buy, Roche cut to hold: RBS

    11/09/09 - Bond / Stock Rating - View Story

  • BioCryst faces tight competition in H1N1 flu drug market

    11/06/09 - Merger / Acquisition - View Story

  • Alnylam Pharmaceuticals signs co-development agreement with Roche for RNAi therapeutics

    11/05/09 - Joint Venture / Alliance - View Story

  • UPDATE: Roche's New Diabetes Drug Works Better Than Byetta

    10/29/09 - Product Announcement - View Story

  • Sumitomo Mitsui Sues Credit Suisse Over Capmark Loan Repayment

    10/20/09 - Lawsuit Filed - View Story

  • Roche raises Tamiflu's sales outlook

    10/16/09 - Financial Announcement - View Story

  • SurModics enters license and development agreement with Roche and Genentech

    10/07/09 - Joint Venture / Alliance - View Story

  • BRIEF-Roche launches new MagNA pure 96 system

    9/30/09 - Product Announcement - View Story

  • Roche U.S. cancer drug trial enrollment suspended

    9/26/09 - Merger / Acquisition - View Story

  • Vivus CEO Ready To Roll Up Sleeves In Finding Qnexa Partner

    9/09/09 - Merger / Acquisition - View Story

  • ImmunoCellular in research and license option deal with Roche

    9/09/09 - Joint Venture / Alliance - View Story

  • UPDATE 1-Roche names Genentech's Soriot new drugs chief

    9/08/09 - Mgmt. Change Leaving - Other - View Story

  • Glance-Europe Factors-Shares set to rise, tracking Asia

    9/08/09 - Mgmt. Change Entering - Other - View Story

  • Roche Holding names Soriot as head of pharma

    9/08/09 - Mgmt. Change Leaving - Other - View Story

News & Analysis

roche holding ag - All News and Analysis

  • Roche to review pay for Genentech staff

    BNET - 2009-10-13

    Employees at Genentech, the US biotech company recently acquired by Roche, are set to receive a much higher proportion of their future remuneration in long-term stock options than their peers across the Swiss pharmaceutical group's operations. Severin Schwan, Roche's chief executive, said that a review of pay at Genentech will...

    Tags: Roche Holding AG, Genentech Inc.

  • Roche and Glaxo to test swine flu drugs

    Financial Times - 2009-09-07

    Roche, the Swiss pharmaceutical group, is funding a study to test the efficacy of its flu drug Tamiflu in combination with rival GlaxoSmithKline's Relenza, in one of several initiatives to extend further the market for its blockbuster antiviral treatment.David Reddy, Roche's pandemic taskforce leader, saidon Monday his company was...

    Tags: Patient, Roche Holding AG, H1N1 Flu, Tamiflu, General News, Health & Healthcare, Financial Times

  • Conagra, Roche, Sanofi and RadioShack Pull Ads From Fox's Beck

    BNET - 2009-08-14

    ConAgra, Roche, Sanofi-Aventis, and RadioShack have all joined the advertisers who have pulled their ads from Glenn Beck's show on Fox News Channel after the host called President Obama a racist. by Jim Edwards

    Tags: Advertisement, RadioShack Corp., Roche Holding AG, Jim Edwards

  • An Osteoporosis Blockbuster for Amgen?

    BNET - 2009-08-11

    By Arlene Weintraub Wall Street has set an exceptionally high bar for Amgen AMGN's new bone-loss treatment. Shares of the world's largest biotechnology company have jumped 27% in the past three months, to 60, largely on news of clinical trials that showed the drug is as at least as effective,...

    Tags: Amgen Inc.

  • Benefits of flu drug questioned

    BNET - 2009-08-10

    The medicine now being widely handed out by the government for treating pandemic flu offers only modest benefit in children and adults in seasonal outbreaks of the virus, according to British researchers. The findings will spark a fresh debate over the wisdom of the UK government ??? and many others...

    Tags: children, flu

Decision Makers

Name (plus bio) Position
Severin Schwan Chief Executive Officer
William M. Burns CEO, Roche Pharma
Erich Hunziker CFO
Jonathan K.C. Knowles Managing Director, Global Pharmaceutical Research
Roche Rolf D Schl Managing Director, Partner
Rolf D Schl Managing Director, Partner
Andres Greuter Compliance Officer
Beatrice Weder
Beatrice Weder di Mauro
Berufliche Laufbahn
Burkhard G Piper
Dr Roche Severin Schwan
Editiones Roche
Eduard E Holdener
Emil Frey Dir
Ernst Peter Fischer
Fr U here Mandate
Fritz Gerber
Gottlieb A. Keller Secretary & Head, Corp Services, HR
Heino von Prondzynski
Ian Massey
James Childress
Leiter der
Leiter Therapiebereichs Des
Lydia Mez
Mina Michal
Myrl Weinberg
Okonomin beim Internationalen WAhrungsfonds
Osamu Nagayama
Peter Brabeck
Ph D in Genetics
Ph D in Genetik
Pierre Jaccoud
Prof Dr Roche Bruno Gehrig
Robert B. Stein
Robert Spreng
Roche Burkhard G Piper
Roche Genetics
Roche Pierre Jaccoud
Roche Sitemap
Seite drucken
Susan Jebb
Werner Schreiber
Ysbrand Portman

Board of Directors

Name (plus bio) Position
Dr Roche Gottlieb Keller Chairman
Andre Hoffman Board of Directors
Andre Hoffmann Vice-Chairman of the Board
Andreas Oeri Board of Directors
Brouno Gehring Vice Chairman
Bruno Gehrig Vice Chairman
DeAnne S. Julius Board of Directors
F Hoffmann Vice chairman
Horst Teltschik Board of Directors
John Irving Bell Board of Directors
Lodewijk J.R. De Vink Board of Directors
Peter Brabeck-Letmathe Board of Directors
Roche Rolf H A nggi Vice-Chairman
Rolf Haenggi Board of Directors
Rolf Hanggi Board of Directors
Walter Frey Board of Directors

Organization Position Status
Roche Holding Ltd. Chief Executive Officer Current
University of Innsbruck Degree, Economics Former
University of Innsbruck Doctorate in Law Former

Organization Position Status
Roche Holding Ltd. CEO, Roche Pharma Current
Roche Products (Proprietary) Limited President Current
Chugai Pharmaceutical Co., Ltd. Board of Directors Current

Organization Position Status
Roche Holding Ltd. CFO Current
F. Hoffmann-La Roche Ltd. CFO Current
Chugai Pharmaceutical Co., Ltd. Board of Directors Current
Genentech, Inc. Board of Directors Current
Holcim Ltd. Board of Directors Current
Diethelm Keller Holding Ltd. Chief Executive Officer Former

Organization Position Status
Roche Holding Ltd. Managing Director, Global Pharmaceutical Research Current
Genentech, Inc. Head, Global Research Current
Genentech, Inc. Board of Directors Current
Chugai Pharmaceutical Co., Ltd. Board of Directors Current
University of East Anglia Honours Degree in Molecular Genetics Former

Organization Position Status
Roche Holding Ltd. Managing Director, Partner Current

Organization Position Status
Roche Holding Ltd. Managing Director, Partner Current

Organization Position Status
Roche Holding Ltd. Compliance Officer Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current
Boehringer Mannheim CEO Former
Boehringer Mannheim Sales Managers Industrial Former

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current
The University of Kansas Former

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current
University of Bern Lawyer LL Former

Organization Position Status
Roche Diagnostics Corporation Secretary Current
Roche Holding Ltd. Secretary & Head, Corp Services, HR Current
Roche Holding Ltd. Board of Directors Current
Roche Diagnostics Corporation Secretary Former

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current
Alcon, Inc. Vice Chairman Current
Nestle S.A. CEO Former

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current
University of Bern Doctorate in economics (Dr Former

Dr. Robert Stein currently serves on the President's Board of Advisors for Science and Innovation for the University of California , is a Member of the Board of Directors of Archemix, and Scientific Advisor to Takeda San Diego. Bob served as the Site President of the Palo Alto , California site of F. Hoffmann-La Roche Ltd from 2003 to 2006. Prior to joining Roche, Bob was the President and Chief Scientific Officer of Incyte Corporation from 2001 to 2003. Bob also served in various roles for Merck & Co., Ligand Pharmaceuticals Inc., the DuPont Merck Pharmaceutical Company and DuPont Pharmaceuticals Company, where he was Executive Vice President of Research and Preclinical Development from 1990 to 1996. Bob received degrees in biology and chemistry from Indiana University , where he was Phi Beta Kappa, and an M.D. and a Ph.D. in physiology and pharmacology from Duke University . Bob completed residency training and is board certified in anatomic and clinical pathology.

Organization Position Status
Kinemed, Inc Chief Executive Officer Current
Roche Holding Ltd. Current
Archemix Corp Board of Directors Current
F. Hoffmann-La Roche Ltd. Site President Former
Incyte Corporation President Former
Ligand Pharmaceuticals Incorporated chief Former
Incyte Corporation Chief Scientific Officer Former
Ligand Pharmaceuticals Incorporated senior vice president Former
Roche Former
Duke University M.D. Former
Indiana University Degrees In Biology Former
Duke University Degrees In Biology Former

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current
Boehringer Mannheim CEO Former
Boehringer Mannheim Regional Sales Manager Former

Organization Position Status
Roche Holding Ltd. Current
Rs-R Former

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current
Alcon, Inc. Former

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Current

Organization Position Status
Roche Holding Ltd. Chairman Current

Organization Position Status
Roche Holding Ltd. Board of Directors Current

Organization Position Status
Living Planet Management Company Chairman Current
Roche Holding Ltd. Vice-Chairman of the Board Current
Givaudan S.A. Vice Chairman Current
Roche Holding Ltd. Member Current
Nestle Uk Ltd Brand Manager Former
Givaudan S.A. Board of Directors Former
INSEAD Masters of Business Administration Former

Organization Position Status
Roche Holding Ltd. Board of Directors Current
University of Basel Medical Studies Former

Organization Position Status
Roche Holding Ltd. Vice Chairman Current

Organization Position Status
Roche Holding Ltd. Vice Chairman Current
Roche Holding Ltd. Board of Directors Current
University of Bern Doctorate in economics (Dr Former

Organization Position Status
The Royal Institute of International Affairs Chairman Current
Roche Holding Ltd. Board of Directors Current
BP plc Board of Directors Current
University of California Ph.D In Economics Former
Iowa State University Ph.D Former
Iowa State University Bsc Former

Organization Position Status
Roche Holding Ltd. Vice chairman Current
Roche Holding Ltd. Chief Executive Officer Former
Diageo plc Board member Former

Organization Position Status
Roche Holding Ltd. Board of Directors Current

Organization Position Status
Roche Holding Ltd. Board of Directors Current

Organization Position Status
Roche Holding Ltd. Board of Directors Current

Peter Brabeck-Letmathe has been a member of the Board since 1997 and served as Vice-Chairman from 2000 to 2005 and since 2008. Since 2008 he has also served on the Chairman's and Governance Committee and the Compensation Committee. On both of these committees he has already served in the past, namely from 2003 to 2005 and 2000 to 2005, respectively. His term as a member of the Board expires at the AGM in 2011. The Board has determined him to be independent under the Group’s independence standards. Peter Brabeck-Letmathe studied Economics at the University of World Trade in Vienna. After graduation in 1968, he joined Nestlé’s sales operations in Austria. His career at Nestlé includes a variety of assignments in several European countries as well as in Latin America. Since 1987, he has been based at Nestlé’s headquarters in Vevey. Since 1997, Mr. Brabeck-Letmathe has served as the Chief Executive Officer of Nestlé and as a member of Nestlé’s Board of Directors. In 2005, Mr. Brabeck-Letmathe was appointed Chairman of the Board of Directors of Nestlé. As of April 10, 2008 he has retired from his function as Chief Executive Officer of Nestlé. Mr. Brabeck is a member of the Boards of Directors of L’Oréal SA, Paris (since 1997) and Roche Holding SA, Basel (since 2000). He is also a member of the Foundation Board of the World Economic Forum and a member of the European Round Table of Industrialists.

Organization Position Status
Credit Suisse Group Vice Chairman Current
Winterthur Schweizerische Versicherungs Gesellschaft Vice Chairman Current
Credit Suisse Group Board of Directors Current
Nestle S.A. Board of Directors Current
L'Oreal S.A. Board of Directors Current
Roche Holding Ltd. Board of Directors Current
World Economic Forum Member, Foundation Board Current
Nestle S.A. Chief Executive Officer Former

Organization Position Status
Roche Holding Ltd. Vice-Chairman Current
Zurich Insurance Company Deputy Chief Executive Officer Former
Zurich Insurance Member Former
Zurich Insurance Company Member Former
Nestle S.A. Vice-Chairman Former

Organization Position Status
Roche Holding Ltd. Board of Directors Current
Roche Holding Ltd. Vice Chairman Current

Organization Position Status
Roche Holding Ltd. Board of Directors Current
Nestle S.A. Second Vice Chairman Current
Nestle S.A. Second Vice Chairman Current
Zurich Insurance Company Deputy Chief Executive Officer Former
Zurich Insurance Company Member Former
Zurich Insurance Member Former
Nestle S.A. Vice-Chairman Former

Organization Position Status
Roche Holding Ltd. Board of Directors Current

Executive News

  • Week of Sept. 7, 2009: Facet Rejects Biogen Idec's Proposal; Roche Announces Management Changes; More...

    Pharmaceutical Technology - 9/09/09 - View Story

  • Roche Names Pharma Chief

    The Wall Street Journal Interactive Edition - 9/09/09 - View Story

  • Roche Announces New Corporate Executive Committee

    Pharma Live - 9/08/09 - View Story

  • Roche moving Clark to CEO of Genentech

    CNBC - 9/08/09 - View Story

  • KineMed to Collaborate with Bristol-Myers Squibb

    TradingMarkets - 6/01/09 - View Story

  • Cancer Drugs: Herceptin News and More

    BusinessWeek - 6/01/09 - View Story

  • Cancer Drugs: News from ASCO

    BusinessWeek - 5/31/09 - View Story

  • KineMed, Inc. Enters Into Collaboration With Bristol-Myers Squibb Company (BMY) (JOBS)

    BioSpace - 5/26/09 - View Story

  • KineMed Enters Into Collaboration With Bristol-Myers Squibb

    Reuters - 5/26/09 - View Story

  • KineMed Enters Into Collaboration With Bristol-Myers Squibb

    Street Insider - 5/26/09 - View Story

  • Roche to Present Major Advances With Targeted Cancer Medicines at ASCO

    Pharma Live - 5/16/09 - View Story

  • Roche Sees Herceptin Growth As Stomach Cancer Drug

    Morningstar.com - 5/15/09 - View Story

  • Roche provides additional donation of 5.65 million packs of Tamiflu to World Health Organization

    Pharma Live - 5/12/09 - View Story

  • Roche Donates Tamiflu to WHO

    The Wall Street Journal Interactive Edition - 5/12/09 - View Story

advertisement
RHHBY $40.10 +0.38 (0.96% )
Volume 263,416
Shares Outstanding 2.8B
Market Cap 112.6B
Year High 42.080
Year Low 26.010
Earnings Per Share 2.37
P/E Ratio 16.9198
Dividend 0.6652
Yield 1.6589
IndustryTop Rated
advertisement
Click Here